All Insights and Resources

Industry Insights

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

6 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Oxford Biomedica Acquires ABL Europe

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

5 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Two female pediatric patients with

FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies

29 November 2023

FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies

FDA investigates T cell malignancy

Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

28 November 2023

Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

Sernova has announced that the

POPULAR NEWS ITEMS

4 December 2023

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

6 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

5 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Positive Clinical Results in Myotubular Myopathy Demonstrate Impact on Respiratory and Motor Functions Amidst Severe Challenges

23 November 2023

Positive Clinical Results in Myotubular Myopathy Demonstrate Impact on Respiratory and Motor Functions Amidst Severe Challenges

Clinical results of a gene

First Patient Enrolled in AskBio’s Phase I Trial for Multiple System Atrophy-Parkinsonian Type (MSA-P) Gene Therapy

22 November 2023

First Patient Enrolled in AskBio’s Phase I Trial for Multiple System Atrophy-Parkinsonian Type (MSA-P) Gene Therapy

AskBio has announced that the

IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients

22 November 2023

IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients

IN8bio, Inc. has presented compelling

First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

16 November 2023

First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

The First regulatory authorization of

RECOMENDED TOPICS

Industry Insights

POPULAR NEWS ITEMS

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

logo_mobile_footer

Company

Resources

Network

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022